•  

Posts Tagged: early-stage investing

Funding for Sinai Health Netherton Syndrome project from partners AmorChem and Evotec

TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide. The project was initiated in partnership with a group of scientists from Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins. These proteins ... Read more

Zucara Therapeutics Announces US$21M Series A Financing

– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund  – TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund Phase 1 and ... Read more

AmacaThera, a TIAP Portfolio Company, Closes Seed Financing Round

TORONTO, Oct. 3, 2019 /PRNewswire/ -- AmacaThera Inc. (www.amacathera.ca) is pleased to announce the closing of its US $3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures. Commenting on the closing of the round, Dr. Molly Shoichet, Ph.D., Co-Founder and Chief Scientific Officer of AmacaThera stated: "We are thrilled to have the Lumira team as part ... Read more

Zucara raises US$3.9M Funding to advance drug for hypoglycemia prevention

Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry B. Helmsley Charitable Trust. As part of the agreement, Helmsley will provide the funding to support preclinical advancement of Zucara’s lead drug candidate. The partnership is structured as a program-related investment (PRI) in the form of a loan to Zucara. Zucara recently defined its lead drug candidate ... Read more

Zucara Therapeutics Inc. Receives Support from NCR-IRAP

VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) and MaRS Innovation have contributed follow on funding to the Company’s existing convertible note. Zucara recently defined its lead drug candidate, ZT-01, and ... Read more

Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia

VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI). This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ... Read more

MaRS Innovation highlighted in the ExcelleNCE newsletter

MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses the success of the MaRS Innovation commercialization model. The article mentions companies such as ScarX Therapeutics, a spin-off of MI and Toronto’s Hospital for Sick Children that is commercializing a topical prescription cream. It also talks about Encycle Therapeutics, a Toronto biotechnology start-up from the University of Toronto, that has developed a fast, ... Read more

Knitt Labs launches KnittBar, raises $50,000 on Kickstarter in six days

UTEST graduate company building a versatile, smart, modular power bar We've all been there: You reach over behind your TV to plug in yet another device to find your power bar’s out of available outlets. You wonder why your electricity bill’s so high and want to know which appliance is the culprit. You forget to turn something off (or did you?) and you’re already halfway to a meeting. Knitt Labs, Inc. has developed KnittBar to solve these frustrating problems for those who are ... Read more

Miroculus acquires Kapplex to advance diagnostics for complex diseases

Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) — Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, today announced an agreement to acquire Toronto-based Kapplex Inc. The Canadian company’s proprietary Digital Microfluidic (DMF) platform is built upon the research of Dr. Aaron Wheeler, a world-leader in microfluidics research at the University of Toronto. This announcement was covered in GenomeWeb and PeHub. When ... Read more

Accel-Rx and BDC Capital make second portfolio investment in ScarX Therapeutics

MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis). Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ... Read more
Page 1 of 41234